VYNE
VYNE Therapeutics Inc. (NASDAQ)
Healthcare — Biotechnology
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey.
Price History
Fundamentals
| Market Cap | $22.37M |
| P/E Ratio (TTM) | - |
| Forward P/E | -0.41 |
| EPS (TTM) | $-0.51 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | -57.40% |
| ROE | -63.16% |
| Debt/Equity | - |
| Recommendation | Buy 2.0 |
| Analyst Target | - |
| Analysts | - |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 52.1 |
| Beta | 2.01 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $1.60 |
| 52-Week Low | $0.28 |
| 50-Day Avg | $0.66 |
| 200-Day Avg | $0.53 |
| Avg Volume | 163.4K |
| Volume | 1.9K |
Performance Analysis
NEUTRALVYNE presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:37 UTC
Back to Screener Export Report